Bionano Genomics, Inc. (NASDAQ: BNGO) today reported certain unaudited preliminary financial results and commercial highlights for the fourth quarter and fiscal year ended December 31, 2025. "2025 was ...

Fourth quarter revenue expected to be $15.9 million to $16.1 million, representing growth of 4% to 5%Full year revenue expected to be $56.5 ...

Over the last decade, the growing disparity between declining professional fee CPT reimbursements and hospital-based ...

Q2 2026 Earnings Call Transcript January 6, 2026 AngioDynamics, Inc. misses on earnings expectations. Reported EPS is ...

Regional variations in market growth reflect differences in healthcare infrastructure and adoption rates, with North America and Asia-Pacific leading the way. Companies operating in the market ...

Monday, January 5, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Meta ...

Our Pilates-obsessed editors tested the best Pilates reformer machines and were wowed by the Original FOLD Reformer for ...

ENVIRONMENT: DESIGN cutting-edge software solutions while working on global projects for a provider of sustainable and cost-effective Solar Energy seeking to fill the role of an Intermediate Front End ...

The new CPT code reflects the latest efficacious medical care available to patients, facilitating adoption and utilization.The assignment of a ...

The market is rapidly transitioning from episodic diagnostics to continuous health monitoring. By 2035, the integration of ...

SkinTE is currently available for investigational use only. Submission of a biologics license application (BLA) to the U.S. Food and Drug Administration is expected in 2026, after which additional ...